STOCK TITAN
  1. Home
  2. News
  3. SRPT

Sarepta Therapeutics Inc - SRPT STOCK NEWS

Welcome to our dedicated news page for Sarepta Therapeutics (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sarepta Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sarepta Therapeutics's position in the market.

News
Sarepta Therapeutics Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Rhea-AI Summary
Sarepta Therapeutics (SRPT) has announced the initiation of screening in Study SRP-9003-301, a Phase 3, multi-national, open-label study of SRP-9003 for the treatment of limb-girdle muscular dystrophy Type 2E (LGMD2E/R4). The study will enroll 15 participants aged 4 and older and uses commercially representative process SRP-9003 material. Early results from the SRP-9003 clinical development program have shown significant protein expression and functional benefits, including slowing disease progression, improving mobility, and enhancing the quality of life for individuals with LGMD2E.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
acquisition clinical trial
-
News
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2023 Net Product Revenue
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) expects a total net product revenue of $1.145 billion for full-year 2023, with ELEVIDYS net product revenue at $131.3 million for the fourth quarter and $200.4 million for full-year 2023, exceeding consensus. RNA-based PMO net product revenue for the fourth quarter and full-year of 2023 is expected to be $234.3 million and $945.0 million, respectively, surpassing the 2023 full-year guidance of $925 million. The year-end 2023 cash, cash equivalents, restricted cash, and investments balance is approximately $1.7 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
News
Sarepta Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
conferences
News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Sarepta Therapeutics, Inc. (SRPT) granted equity awards to 4 individuals hired in December 2023, in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase 3,850 shares of Sarepta's common stock and 1,900 restricted stock units. The options have an exercise price of $96.43 per share, with vesting schedules over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label to include Duchenne Muscular Dystrophy Patients without Restriction to Age or Ambulatory Status
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has submitted an efficacy supplement to the Biologics License Application for ELEVIDYS to expand its labeled indication for the treatment of Duchenne muscular dystrophy patients. The supplement is supported by results from global clinical studies and has been submitted to the U.S. FDA with a request for Priority Review. Sarepta has also completed the EMBARK postmarketing requirement and submitted the request to FDA for conversion from accelerated approval to traditional approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
none
-
News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards on November 30, 2023, to 13 individuals as an inducement to employment. The employees received options to purchase 14,250 shares of Sarepta's common stock and 7,350 restricted stock units. The options have an exercise price of $81.28 per share, with vesting schedules over four years, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags
none
News
Sarepta Therapeutics to Present at the UBS Biopharma Conference
Rhea-AI Summary
Sarepta Therapeutics, Inc. will participate in a fireside chat at the UBS Biopharma Conference on November 9, 2023. The presentation will be webcast live and archived on Sarepta's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
conferences
-
News
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate Developments
Rhea-AI Summary
Sarepta Therapeutics reported net product revenues of $69.1 million for Q3 2023, with total revenues reaching $331.8 million. Non-GAAP earnings stood at approximately $38.0 million. The company launched ELEVIDYS, the first gene therapy for boys with Duchenne muscular dystrophy, and achieved profitability on a non-GAAP basis. The topline results from the EMBARK study support the conclusion that ELEVIDYS modifies the course of the disease in patients with Duchenne.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
earnings
-
News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Sarepta Therapeutics, Inc. granted equity awards to 12 new employees in October 2023. The employees received options to purchase 10,675 shares of Sarepta's common stock and 6,050 restricted stock units (RSUs). The options have an exercise price of $67.31 per share, with vesting occurring over a four-year period. The RSUs will also vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.68%
Tags
none
News
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
Rhea-AI Summary
Sarepta Therapeutics announced topline results from the EMBARK study of ELEVIDYS in patients with Duchenne muscular dystrophy. The study showed an increase in motor function in patients treated with ELEVIDYS compared to placebo. The primary endpoint was not met, but statistically significant results were observed in key secondary endpoints. No new safety signals were observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.47%
Tags
clinical trial
Stock SRPT logo
Sarepta Therapeutics Inc

Nasdaq:SRPT

SRPT Rankings

#718 Ranked by Market Cap
#2404 Ranked by Stock Gains
N/A Ranked by Dividends

SRPT Stock Data

11.53B
89.61M
4.3%
87.88%
4.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About SRPT

sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.